Eicosanoid Pathways and Inflammation in Sickle Cell Vaso-Occlusion: A Review

Abstract

Sickle cell anemia (SCA) is a genetic blood disorder characterized by the production of abnormal hemoglobin S, leading to the deformation of red blood cells (RBCs) into a sickle shape. This deformation results in recurrent vaso-occlusive crises (VOCs), a hallmark of the disease, which are driven by complex interactions between sickled RBCs, inflammation, and endothelial dysfunction. Eicosanoids, bioactive lipid mediators derived from arachidonic acid, play a critical role in the inflammatory response associated with VOCs. This review explores the various eicosanoid pathways involved in SCA, focusing on the roles of prostaglandins, leukotrienes, and lipoxins in modulating inflammation and vascular function. The dysregulation of eicosanoid synthesis and metabolism significantly contributes to the pathophysiology of VOCs in SCA. Elevated levels of pro-inflammatory prostaglandins and leukotrienes exacerbate inflammation, increase vascular permeability, and promote leukocyte adhesion, leading to microvascular obstruction and tissue ischemia. Conversely, the production of anti-inflammatory lipoxins may be impaired, further perpetuating the inflammatory response. Therapeutic strategies targeting eicosanoid pathways offer promising avenues for improving clinical outcomes in patients with SCA. Interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), leukotriene receptor antagonists, and lipoxin analogues may help mitigate inflammation and prevent VOCs. Keywords: Sickle cell anemia, vaso-occlusive crisis, eicosanoids, inflammation, leukotrienes, prostaglandins, arachidonic acid, COX enzymes, LOX enzymes, therapeutic strategies